MedTrace Logo

Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer

NCT00460551 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2011-12-06

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to investigate if treatment with zalutumumab in combination with chemotherapy and radiotherapy (chemo-radiation) will lead to a prolonged life in patients with lung cancer compared to patients treated with chemo-radiation alone.

Conditions

  • Non Small Cell Lung Cancer

Interventions

BIOLOGICAL

Zalutumumab

8 mg/kg

DRUG

Induction chemotherapy

Combination of cisplatin and docetaxel administered as two cycles given every three weeks

RADIATION

Radiotherapy

64 Gy in 32 fractions over 6.5 weeks

Sponsors & Collaborators

  • Genmab

    lead INDUSTRY

Principal Investigators

  • Steen Lisby, MD, PHD · Genmab employee

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United States
  • Belgium
  • France
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00460551 on ClinicalTrials.gov